QBiotics

    OverviewSuggest Edit

    QBiotics Group is a life sciences company that discovers, develops, and commercializes pharmaceuticals for human and veterinary markets. It focuses on cancer, specifically solid tumours, and chronic wound management areas. The company develops tigilanol tiglate (EBC-46), an oncology product for the treatment of solid tumour cancers, and EBC-1013, a wound healing product.
    TypePrivate
    Founded2000
    HQToowong, AU
    Websiteqbiotics.com

    Latest Updates

    Employees (est.) (Sept 2021)26(+9%)
    Cybersecurity ratingAMore
    Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
    Banner background

    Key People/Management at QBiotics

    Susan Foden

    Susan Foden

    Non-Executive Director
    Neville Mitchell

    Neville Mitchell

    Non-Executive Director
    Bruce Robinson

    Bruce Robinson

    Non-Executive Director
    Show more

    QBiotics Office Locations

    QBiotics has offices in Toowong, Cairns City, Taringa and Yungaburra
    Toowong, AU (HQ)
    24 Ebor St
    Cairns City, AU
    15 Lake St
    Taringa, AU
    165 Moggill Rd
    Show all (4)

    QBiotics Financials and Metrics

    Summary Metrics

    Founding Date

    2000

    QBiotics Cybersecurity Score

    Cybersecurity ratingPremium dataset

    A

    92/100

    SecurityScorecard logo

    QBiotics Online and Social Media Presence

    Embed Graph

    QBiotics News and Updates

    QBiotics kündigt klinische Zusammenarbeit mit MSD bei inoperablem Melanom an

    Zusammenarbeit mit MSD zur Untersuchung des Leitmoleküls Tigilanol Tiglat von QBiotics in Kombination mit Keytruda® (Pembrolizumab) Tigilanol Tiglat ist ein neuartiges kleines Molekül, das sich als intratumorale Behandlung von soliden Tumoren in der Entwicklung befindet Das Melanom ist...

    QBiotics kondigt klinische samenwerking aan met MSD gericht op inoperabel melanoom

    Samenwerking met MSD om de combinatie van QBiotics' loodverbinding tigilanol-tiglaat met Keytruda® (pembrolizumab) te onderzoeken Tigilanol-tiglaat is een nieuw, klein molecuul dat ontwikkeld wordt als intratumorale behandeling voor solide tumoren Melanoom is de tweede menselijke...

    QBiotics fait part de sa collaboration clinique avec MSD dans le ciblage de mélanomes non résécables

    Collaboration avec MSD afin d'étudier la molécule phare de QBiotics, le tiglate de tigilanol en association avec le Keytruda® (pembrolizumab) Le tiglate de tigilanol est une petite molécule nouvelle en cours de développement comme traitement intratumoral de tumeurs solides Le mélanome...

    QBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma

    MSD collaboration to investigate QBiotics' lead molecule tigilanol tiglate in combination with Keytruda® (pembrolizumab) Tigilanol tiglate is a novel, small molecule that is being developed as an intratumoural treatment for solid tumours Melanoma is the second human application being...

    QBiotics Frequently Asked Questions

    • When was QBiotics founded?

      QBiotics was founded in 2000.

    • Who are QBiotics key executives?

      QBiotics's key executives are Susan Foden, Neville Mitchell and Bruce Robinson.

    • How many employees does QBiotics have?

      QBiotics has 26 employees.

    • Who are QBiotics competitors?

      Competitors of QBiotics include Capella Therapeutics, Vectorite Biomedical and Repertoire Immune Medicines.

    • Where is QBiotics headquarters?

      QBiotics headquarters is located at 24 Ebor St, Toowong.

    • Where are QBiotics offices?

      QBiotics has offices in Toowong, Cairns City, Taringa and Yungaburra.

    • How many offices does QBiotics have?

      QBiotics has 4 offices.